«
Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»
Not exact matches
Led by Nina Bhardwaj, M.D., director of immunotherapy, the
Personalized Genomic
Vaccine trial uses the genetic sequence of a patient's tumor to create a customized v
Vaccine trial uses the genetic sequence of a patient's
tumor to create a customized
vaccinevaccine.
BioNTech hit the headlines in July when its experimental
personalized cancer
vaccine, tailored to the
tumors of individual patients, kept disease in check in an early - stage clinical trial.
As researchers learn more about genetic profile of various cancers, other work is charging ahead to deliver
personalized vaccines targeted to a patient's own
tumor cells
Another focus in Chan's group is
personalized vaccines that are based on neoantigens identified by sequencing a patient's
tumor.
Another possible application for the new machine is generating peptides that could be used as
personalized cancer
vaccines targeting unique proteins found in individual patients»
tumors.
The
personalized vaccine is made from patients» own immune cells, which are exposed in the laboratory to the contents of the patients»
tumor cells, and then injected into the patients to initiate a wider immune response.
Each
vaccine is essentially
personalized for the individual patient, using the patient's own
tumor which has a unique set of mutations and thus a unique presentation to the immune system.
Moderna is also doing animal safety tests of a
personalized cancer
vaccine that would code for immune - activating proteins unique to a person's cancer cells, based on genetic sequencing of their
tumor.
«This broad implication is in contrast to a more traditional
vaccine - based approach, which requires a specialist to surgically remove
tumor samples from a patient's body then create a
personalized vaccine approach for one specific patient.»
Now, a new approach that tailors a
personalized vaccine to the mutated proteins in an individual's
tumor appears to have prevented early relapses in 12 people with skin cancer.
«Each patient is different, so we're developing a
personalized vaccine based on specific targets we identify on a patient's
tumor,» Overman says.
My studies of cancer genomes have led to characterization of multiple pediatric and adult
tumor types, to development of methods that identify and characterize changes in genomic heterogeneity, to defining acquired resistance mechanisms to targeted therapies and to designing novel,
personalized vaccines for individual patients.
Physicians with the
Personalized Medicine Program at The Tisch Cancer Institute have initiated a phase I proof - of - concept study, a fully personalized multipeptide therapeutic vaccine designed to target tumor - derived neoantigens for individu
Personalized Medicine Program at The Tisch Cancer Institute have initiated a phase I proof - of - concept study, a fully
personalized multipeptide therapeutic vaccine designed to target tumor - derived neoantigens for individu
personalized multipeptide therapeutic
vaccine designed to target
tumor - derived neoantigens for individual patients.
Provenge and other therapeutic
vaccines involve
personalized therapy that targets the patient's specific
tumor.